Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 2/20 | 0.43 |
| ▸ | FAAH | O00519 | 2/20 | 0.42 |
| ▸ | ACHE | P22303 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.41 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4824611 | 1.00 | TDP1 (0.47) | TDP1ALDH1A1MAPTATMGLA | |
| SCHEMBL7168254 | 0.90 | HSPB1 (0.45) | TDP1ALDH1A1MAPTATMGLA | |
| SCHEMBL6215780 | 0.84 | ALDH1A1 (0.48) | ALDH1A1MAPTGLASMN1; SMN2L3MBTL1 | |
| SCHEMBL4211458 | 0.84 | NPC1 (0.60) | TDP1ALDH1A1MAPTGLARAB9A | |
| SCHEMBL4211452 | 0.84 | NPC1 (0.60) | TDP1ALDH1A1MAPTGLARAB9A | |
| SCHEMBL3808783 | 0.84 | NPC1 (0.60) | TDP1ALDH1A1MAPTGLARAB9A | |
| SCHEMBL1202697 | 0.82 | ALDH1A1 (0.49) | TDP1ALDH1A1MAPTATMRAB9A | |
| SCHEMBL6311506 | 0.82 | PKM (0.51) | TDP1ALDH1A1MAPTGLARAB9A | |
| SCHEMBL6216795 | 0.82 | PKM (0.51) | TDP1ALDH1A1MAPTGLARAB9A | |
| SCHEMBL3859657 | 0.82 | PKM (0.51) | TDP1ALDH1A1MAPTGLARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090306141-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2009-12-10 | — | — | US | disclosed |
| US-7528156-B2 | Compounds | ASTRAZENECA AB (SE) | 2009-05-05 | — | — | US | disclosed |
| US-7388020-B2 | Benzimidazol derivatives modulate chemokine receptors | ASTRAZENECA AB (SE) | 2008-06-17 | — | — | US | disclosed |
| US-7345063-B2 | Amides, preparation and therapeutic use as modulators of CCR-receptor activity | ASTRAZENECA AB (SE) | 2008-03-18 | — | — | US | disclosed |
| EP-1372651-B1 | NOVEL AMIDES, PREPARATION AND THERAPEUTIC USE AS MODULATORS OF CCR-RECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2007-03-07 | — | — | EP | disclosed |
| US-6951874-B2 | Compounds | ASTRAZENECA AB (SE) | 2005-10-04 | — | — | US | disclosed |
| US-6943188-B2 | Hydroxyalkyl compounds | ASTRAZENECA AB (SE) | 2005-09-13 | — | — | US | disclosed |
| US-6927222-B2 | 1,3,4,5-tetrahydro-pyrido(4,3-b)indole-2-yl derivative useful for treating rheumatoid arthritis, chronic obstructive pulmonary disease, asthma and multple sclerosis | ASTRAZENECA AB (SE) | 2005-08-09 | — | — | US | disclosed |
| US-6911458-B2 | Compounds | ASTRA ZENECA (SE) | 2005-06-28 | — | — | US | disclosed |
| EP-1263724-B1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2005-05-18 | — | — | EP | disclosed |
| EP-1373248-A1 | BENZIMIDAZOL DERIVATIVES MODULATE CHEMOKINE RECEPTORS | AstraZeneca AB (SE) | 2004-01-02 | — | — | EP | disclosed |
| US-20030162772-A1 | Novel compounds | ASTRAZENECA AB (SE) | 2003-08-28 | — | — | US | disclosed |
| US-20030158225-A1 | Novel compounds | ASTRAZENECA AB (SE) | 2003-08-21 | — | — | US | disclosed |
| US-20030149047-A1 | Novel compounds | ASTRAZENCA AB (SE) | 2003-08-07 | — | — | US | disclosed |
| US-20030144267-A1 | Novel compounds | ASTRAZENECA AB (SE) | 2003-07-31 | — | — | US | disclosed |
| EP-1299357-A1 | NOVEL COMPOUNDS | AstraZeneca AB (SE) | 2003-04-09 | — | — | EP | disclosed |
| WO-2002074763-A9 | BENZIMIDAZOL DERIVATIVES MODULATE CHEMOKINE RECEPTORS | ASTRAZENECA AB (SE) | 2002-10-24 | — | — | WO | disclosed |
| WO-2002076457-A1 | NOVEL AMIDES, PREPARATION AND THERAPEUTIC USE AS MODULATORS OF CCR-RECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2002-10-03 | — | — | WO | disclosed |
| WO-2002074763-A1 | BENZIMIDAZOL DERIVATIVES MODULATE CHEMOKINE RECEPTORS | ASTRAZENECA AB (SE) | 2002-09-26 | — | — | WO | disclosed |
| WO-2001098273-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2001-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158225-A1 | Novel compounds | UGT2B7, RPS4Y1, RPS4X | TDP1 4218/4885ALDH1A1 1012/4885MAPT 3699/4885 |
| US-20090306141-A1 | Novel Compounds | CHRM2, CHRM1, C1R | TDP1 3305/4885ALDH1A1 1779/4885MAPT 4084/4885 |
| US-20030149047-A1 | Novel compounds | RPS4Y1, RPS4X, RPS6 | TDP1 3881/4885ALDH1A1 924/4885MAPT 3658/4885 |
| US-20030162772-A1 | Novel compounds | RPS4X, RPS4Y1, MRPS18A | TDP1 4297/4885ALDH1A1 949/4885MAPT 3867/4885 |
| US-20030144267-A1 | Novel compounds | RPS4X, RPS4Y1, UGT2B7 | TDP1 4435/4885ALDH1A1 1466/4885MAPT 3632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.